versus 4%; $p=0.03$), and lower prevalence of Raynaud's phenomenon (65% versus 82%, $p=0.002$). Regarding cumulative manifestations, myositis (51% versus 15%; $p<0.001$), arthritis (43% versus 22%; $p=0.001$), and interstitial lung disease (ILD) (60% versus 45%, $p=0.014$) were more prevalent in patients with anti-PM/Scl antibodies. In fact, those patients with anti-PM/Scl antibodies presented with FVC ($77.4\% \pm 23.1\%$ versus $85.8\% \pm 23.1\%$; $p=0.006$) and more severe ILD defined as FVC $<70\%$ (41% versus 24%; $p=0.004$). Death rate was similar in patients with and without PM/Scl antibodies (18% versus 17%; $p=0.871$). We did not find differences in terms of death rate nor in the causes of death (SSc and non-SSc related) according to the anti-PM/Scl antibodies profile. The 5- and 10-years survival rates of patients with anti-PM/Scl antibodies were 91% and 82% respectively, without differences with those without these antibodies (93% and 85%, respectively).

Conclusion: In Spanish SSc patients, the presence of anti-PM/Scl antibodies confer a distinctive clinical profile. However, anti-PM/Scl antibodies do not play a role in the prognosis of these patients.

References:

- [1] Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: an update. *Clin Rev Allergy Immunol* 2020;58(1):40-51. doi: 10.1007/s12016-018-8718-8.

Acknowledgments: We gratefully acknowledge all investigators who are part of the RESCLE Registry. We also thank the RESCLE Registry Coordinating Centre, S&H Medical Science Service, for their quality control data, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma de Madrid and Statistical Advisor S&H Medical Science Service for the statistical analysis of the data presented in this paper.

Disclosure of Interests: Nerea Iniesta-Arandia: None declared, Gerard Espinosa Speakers bureau: Glaxo-Smith-Kline, Janssen, Boehringer, Rovi, Alfredo Guillen del Castillo: None declared, Carlos Tolosa Consultant of: Actelion pharmaceuticals, GSK, MSD., Gema Maria Lledó: None declared, Dolores Colunga Argüelles Consultant of: Actelion pharmaceuticals, GSK, MSD., Cristina González-Echávarri: None declared, Luis Sáez-Comet: None declared, Norberto Ortego: None declared, Jose Antonio Vargas-Hitos: None declared, Manuel Rubio-Rivas: None declared, Mayka Freire: None declared, Juan José Rios: None declared, Monica Rodríguez-Carballeira: None declared, Luis Trapiella Martínez: None declared, Vicent Fonollosa Pla Speakers bureau: Actelion, Carmen Pilar Simedón-Aznar Consultant of: Actelion pharmaceuticals, GSK, MSD., on behalf of RESCLE Investigators, Autoimmune Diseases Study Group (GEAS): None declared

DOI: 10.1136/annrheumdis-2020-eular.3304

SAT0317

HDL-CHOLESTEROL EFFLUX CAPACITY IS DOWNREGULATED IN PATIENTS WITH SYSTEMIC SCLEROSIS.

I. Ferraz-Amaro¹, D. F. Esmeralda¹, V. Hernández-Hernández¹, H. Sánchez-Pérez¹, L. De Armas-Rillo², E. Armas González³, J. D. Machado⁴, F. Díaz-González¹. ¹Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Santa Cruz de Tenerife, Spain; ²Universidad Europea de Canarias, Santa Cruz de Tenerife, Spain; ³Universidad de La Laguna, Departamento de Bioquímica, Microbiología, Biología Celular y Genética, La Laguna, Spain; ⁴Universidad de La Laguna, Santa Cruz de Tenerife, Spain

Background: It is well established that patients with systemic sclerosis (SS) show a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC) is the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages. CEC has been linked to cardiovascular events in the general population and to subclinical atherosclerosis in patients with rheumatoid arthritis and systemic lupus erythematosus.

Objectives: The main purpose of our study was to assess, for the first time, whether CEC is disrupted in patients with SS compared to controls. We also aimed to identify patients' characteristics that could explain such potential CEC disturbance.

Methods: Cross-sectional study that encompassed 188 individuals; 73 SS patients and 115 age- and sex-matched controls. CEC, using an *in vitro* assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SS-related data could explain CEC differences.

Results: CEC was downregulated in SS patients as compared to controls (beta coefficient -6 [95%CI -10 -2] %, $p=0.002$). This occurred independently of traditional cardiovascular risk factors, statin use or other variations in the lipid profile produced by the disease. Demographics and lipid profile were, in general, not related with CEC in both patients and controls. In this sense, only abdominal circumference showed a positive association with CEC in patients (beta coefficient 0.09 [95%CI 0.03-0.14], $p=0.002$) but not in controls. Similarly, no traditional

cardiovascular risk factors were related with CEC in both populations. Regarding lipid profile, no correlations were identified between the standard lipid profile molecules and CEC. Remarkably, the use of statins was not related to CEC in both patients and controls. Lastly, concerning SS related data, a negative association between mRSS and CEC was identified (beta coef. -1.08 [95%CI -2.03 -0.12] %, $p=0.028$).

Skin thickness through modified Rodnan (mRSS) was positively related to age and the presence of hypertension, but negatively associated with apolipoprotein B, apo B:A1 ratio, and CEC when univariate correlations were assessed (Table 4). When the relation of mRSS to these lipid-related molecules was adjusted for traditional CV risk factors, the statistical significance of mRSS with those molecules was maintained. Moreover, when the relation between mRSS and CEC was additionally adjusted for other lipid-related molecules, its significance was conserved (beta coef. -1.35 [95%CI -2.62 -0.08] %, $p=0.038$).

Conclusion: CEC is downregulated in SS patients independently of other inflammation-related lipid profile modifications that occur in the disease. Skin thickness is independent and inversely associated with CEC in SS patients.

Disclosure of Interests: Iván Ferraz-Amaro Grant/research support from: Pfizer, Abbvie, Speakers bureau: Pfizer, Abbvie, MSD., delgado frias esmeralda Speakers bureau: Pfizer, Abbvie, MSD, Vanessa Hernández-Hernández Speakers bureau: Pfizer, Abbvie, MSD, Hiurma Sánchez-Pérez: None declared, Laura de Armas-Rillo: None declared, Estefania Armas González: None declared, Jose David Machado: None declared, Federico Díaz-González Grant/research support from: Abbvie, Pfizer, MSD, Speakers bureau: Abbvie, Pfizer, MSD

DOI: 10.1136/annrheumdis-2020-eular.620

SAT0318

GENERALIZED INDICATOR OF RAYNAUD'S PHENOMENON EXPRESSION FOR EVALUATION OF CLINICAL EFFICACY OF PROSTANOID THERAPY

I. Gaisin¹, Z. Bagautdinova², M. Glavatskikh³, N. Maximov¹, R. Valeeva¹, O. Desinova⁴, R. Shayakhmetova⁴. ¹Izhevsk State Medical Academy, Izhevsk, Russian Federation; ²Clinical Diagnostic Centre of the Udmurt Republic, Izhevsk, Russian Federation; ³Udmurt State University, Izhevsk, Russian Federation; ⁴VA. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: Raynaud's phenomenon (RP) secondary to rheumatic diseases (RD) can progress to irreversible tissue damage with digital ulceration, scarring and, rarely, gangrene requiring amputation¹. Current medical treatments for RP are far from ideal: they are often either ineffective and/or poorly tolerated, thus a significant proportion of patients discontinue drug therapy².

Objectives: To determine RP expression levels and to evaluate the long-term efficacy of iloprost and alprostadil in RP patients with RD.

Methods: Indicated therapy with intravenous iloprost (n=10), alprostadil (n=17) or their combinations (n=13) was carried out for three years in patients with secondary RP in RD. Frequency of Raynaud's attacks, digital ulcers (DU) formation and pain intensity on visual analogue scale (VAS) were evaluated. A control group included 30 patients with RP in RD who did not receive prostanoid therapy. By factor analysis method a generalized index of RP expression was identified, on the basis of which levels of RP expression were determined.

Results: "RP expression" scale, revealed as an indicator of RP generalized manifestation, was an average value of two subscales: (1) consisted of 4 indices "DU", "digital pitting scars", "phalange amputation" and "frequency of Raynaud's attack"; (2) included 3 indicators: "intensity of pain", "duration of illness", "whitening of fingers". Correlation of subscales showed their reliability ($r=0.294$, $p=0.053$). RP final expression (severity) was 1.51 ± 0.86 . A low level of RP expression had values below 0.65, a high level – over 2.37. At baseline, the high level of RP severity was defined in 16 (22.9%) patients, medium – in 43 (61.4%), low – in 11 (15.7%).

RP treatment with iloprost was effective in the healing of DU in 100% of patients and led to decrease of RP expression generalized index from 2.25 [1; 3] to 1.75 [1; 2] ($p=0.012$). Alprostadil therapy reduced pain intensity on VAS ($p<0.05$) and numbness during Raynaud's attacks ($p<0.01$) and decreased RP expression from 1 [1; 2] to 1 [0.5; 1.5] ($p=0.038$). Patients on prostanoids combination had new DU and amputations; pain intensity reduced by 47% ($p<0.05$), RP expression generalized indicator did not change.

Conclusion: Based on RP clinical manifestations in RD patients, a generalized index of RP expression was identified and levels of RP severity were determined. Treatment with iloprost or alprostadil has significant effects on reducing the clinical manifestations of RP with a corresponding decrease in its severity. Iloprost is indicated in patients with medium and high levels of RP expression index, alprostadil – with medium and low index and non-effectiveness of calcium channel blockers.